Diligent Investors LLC bought a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 2,986 shares of the biopharmaceutical company’s stock, valued at approximately $214,000.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the stock. State Street Corp raised its position in Gilead Sciences by 4.5% in the fourth quarter. State Street Corp now owns 60,448,831 shares of the biopharmaceutical company’s stock worth $4,328,739,000 after buying an additional 2,587,072 shares during the period. Bank of New York Mellon Corp raised its position in Gilead Sciences by 0.6% in the third quarter. Bank of New York Mellon Corp now owns 26,786,930 shares of the biopharmaceutical company’s stock worth $2,119,382,000 after buying an additional 169,701 shares during the period. BlackRock Fund Advisors raised its position in Gilead Sciences by 6.8% in the third quarter. BlackRock Fund Advisors now owns 26,032,555 shares of the biopharmaceutical company’s stock worth $2,059,696,000 after buying an additional 1,663,268 shares during the period. Parnassus Investments CA raised its position in Gilead Sciences by 27.5% in the third quarter. Parnassus Investments CA now owns 10,790,358 shares of the biopharmaceutical company’s stock worth $853,733,000 after buying an additional 2,329,874 shares during the period. Finally, Boston Partners raised its position in Gilead Sciences by 51.7% in the third quarter. Boston Partners now owns 9,855,682 shares of the biopharmaceutical company’s stock worth $779,781,000 after buying an additional 3,358,289 shares during the period. 74.19% of the stock is owned by institutional investors and hedge funds.

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Shares of Gilead Sciences, Inc. (NASDAQ:GILD) opened at 68.71 on Tuesday. Gilead Sciences, Inc. has a 1-year low of $65.38 and a 1-year high of $103.10. The stock has a market capitalization of $89.81 billion, a P/E ratio of 6.91 and a beta of 1.11. The stock’s 50 day moving average price is $69.69 and its 200-day moving average price is $73.79.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Tuesday, February 7th. The biopharmaceutical company reported $2.70 EPS for the quarter, topping analysts’ consensus estimates of $2.61 by $0.09. Gilead Sciences had a return on equity of 92.36% and a net margin of 44.43%. The business earned $7.30 billion during the quarter, compared to analysts’ expectations of $7.16 billion. During the same period in the previous year, the firm earned $3.32 earnings per share. The firm’s quarterly revenue was down 13.9% compared to the same quarter last year. Equities research analysts anticipate that Gilead Sciences, Inc. will post $8.24 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, March 30th. Investors of record on Thursday, March 16th will be paid a dividend of $0.52 per share. The ex-dividend date of this dividend is Tuesday, March 14th. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.47. This represents a $2.08 dividend on an annualized basis and a dividend yield of 3.03%. Gilead Sciences’s payout ratio is 18.91%.

Your IP Address:

GILD has been the subject of a number of recent analyst reports. Jefferies Group LLC reiterated a “buy” rating and issued a $91.00 price target on shares of Gilead Sciences in a research report on Wednesday, January 4th. Royal Bank of Canada reiterated a “buy” rating and issued a $90.00 price target on shares of Gilead Sciences in a research report on Tuesday, January 3rd. Cowen and Company set a $100.00 price target on Gilead Sciences and gave the company a “buy” rating in a research report on Wednesday, January 18th. TheStreet lowered Gilead Sciences from a “b-” rating to a “c+” rating in a research report on Wednesday, January 25th. Finally, Credit Suisse Group AG reiterated a “buy” rating and issued a $79.00 price target on shares of Gilead Sciences in a research report on Wednesday, March 1st. One equities research analyst has rated the stock with a sell rating, ten have given a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $83.19.

In related news, insider John C. Martin sold 73,337 shares of Gilead Sciences stock in a transaction on Tuesday, January 3rd. The stock was sold at an average price of $73.59, for a total transaction of $5,396,869.83. Following the completion of the sale, the insider now directly owns 3,204,433 shares of the company’s stock, valued at $235,814,224.47. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 1.40% of the stock is owned by insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.

5 Day Chart for NASDAQ:GILD

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.